Clinical Scorecard: Could Topical Delgocitinib Treat Capecitabine-Associated Hand–Foot Syndrome?
At a Glance
Category
Detail
Condition
Clinical topic addressed by the source article: Could Topical Delgocitinib Treat Capecitabine-Associated Hand–Foot Syndrome?
Key Mechanisms
Delgocitinib is a topical pan-JAK inhibitor targeting JAK1, JAK2, JAK3, and TYK2; the source describes cytokine pathways implicated in cutaneous inflammation, pain, pruritus, and barrier dysfunction.
Target Population
Population described in the source article.
Care Setting
Delgocitinib was used off-label for capecitabine-induced HFS after written informed consent.
Key Highlights
Both patients received topical delgocitinib twice daily on the palms and soles for 6 weeks as monotherapy.
One patient's CTCAE grade improved from 3 to 1 and HFS-14 score from 73.5 to 17.6; capecitabine was continued.
The other patient's CTCAE grade remained 3 and HFS-14 score changed from 76.5 to 67.6; capecitabine interruption was required.
The discordant outcomes in this two-patient case series cannot establish delgocitinib efficacy.
Larger prospective studies are needed to define the role of topical JAK inhibitors in HFS and identify patients more likely to benefit.
Guideline-Based Recommendations
Diagnosis
Assess HFS clinically; the report evaluated severity using CTCAE v6.0 and quality of life using the HFS-14 instrument.
Management
Prevention described in the article includes patient education, avoiding friction, pressure, heat, and trauma, regular emollient use, removal of hyperkeratosis, comfortable shoes, and early dermatologic assessment.
Treatment generally includes high-potency topical corticosteroids, urea or other keratolytics, analgesics, wound care, and management of fissures.
For severe or refractory HFS, modification of the oncologic strategy may be required.
Topical delgocitinib was used off-label in two refractory cases; this limited experience does not establish efficacy.
Monitoring & Follow-up
The reported patients were closely monitored by dermatology while capecitabine was continued after individualized assessment with the oncology team.
Clinical examination and HFS-14 were used to assess outcomes at 6 weeks.
Risks
HFS may cause burning, dysesthesia, erythema, swelling, painful desquamation, fissures, blisters, or ulceration.
HFS can disrupt daily activities and quality of life and may require chemotherapy dose reduction, temporary interruption, or discontinuation.
The article reports only two patients and discordant outcomes; efficacy and patient selection remain uncertain.
Patient & Prescribing Data
Two patients with metastatic breast cancer receiving capecitabine monotherapy developed grade 3 HFS despite 2 months of clobetasol propionate 0.05% cream under occlusion once daily and urea 30%. HFS transiently improved to grade 2 during treatment, then returned to grade 3.
Clinical Best Practices
Educate patients about HFS prevention, including avoiding friction, pressure, heat, and trauma and using comfortable shoes.
Use regular emollients and consider removal of hyperkeratosis; arrange early dermatologic assessment.
Assess severity and quality-of-life impact, and coordinate decisions about anticancer treatment with the oncology team.
Discuss off-label use and obtain informed consent when considering delgocitinib for capecitabine-associated HFS.
